Results of allogeneic stem cell transplantation in T-cell lymphoma patients beyond first CR
| Reference . | n . | Histology; no. of patients* . | Median age, y . | NRM . | GVHD . | Relapse . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| 47 | 126 | NOS, 63 | 38 | MAC 34% | NR | MAC 37% | MAC 29% | MAC 31% |
| AITL, 12 | at 3 y | at 3 y | at 3 y | at 3 y | ||||
| ALCL, 51 | RIC 27% | RIC 42% | RIC 32% | RIC 50% | ||||
| at 3 y | at 3 y | at 3 y | at 3 y | |||||
| 52 | 77 | PTCL, 27 | 41 | 34% at 5 y | Acute 21% (grade 3-4) chronic NR | NR | 58% at 5 y | 63% at 5 y |
| AITL, 11 | 47 | 80% at 5 y | 80% at 5 y | |||||
| ALCL, 27 (8 ALK+) | 26 | 48% at 5 y | 55% at 5 y | |||||
| Other, 12 | 35 | NR | 33% at 5 y | |||||
| 93 | 66 | NOS, 23 | NR | 29% at day 100 | NR | NR | 46% at 1 y | 48% at 1 y |
| AITL, 12 | ||||||||
| ALCL, 11 | ||||||||
| T-LBL, 6 | ||||||||
| T-PLL, 7 | ||||||||
| Other, 7 | ||||||||
| 53 | 52 | NOS, 23 | 47 | 12% at 5 y | Acute, 22% (grade 2-4) chronic, 27% | 49% at 5 y | 39% at 5 y | 45% at 5 y |
| AITL, 9 | 44% at 5 y | 66% at 5 y | ||||||
| ALCL, 11 | 45% at 5 y | 54% at 5 y | ||||||
| No difference by histology | No difference by histology | |||||||
| 54 | 52 | NOS, 20 | 46 | 27% at 3 y | Acute, 21% | 43% at 3 y | 30% at 3 y | 41% at 3 y |
| AITL, 5 | (grade 2-4) | |||||||
| ALCL, 6 | Chronic, 27% | |||||||
| Other, 21 | (extensive) | |||||||
| 55 | 45 | AITL, 45 | 48 | 25% at 1 y | Acute, 29% (grade 2-4) Chronic, 54% | 20% at 3 y | 53% at 3 y | 64% at 3 y |
| 56 | 37 | NOS, 8 | 40 (50 for CTCL) | 29% at 5 y | Acute, 51% | 24% at 5 y | 47% at 5 y | 52% at 5 y |
| AILT, 4 | Chronic, 62% | |||||||
| ALCL, 6 (3 ALK+) | ||||||||
| Other, 6 | ||||||||
| CTCL, 13 | ||||||||
| 57 | 27 | NOS, 5 | 50 | 22% at 2 y | Acute, 33% (grade 2-3) Chronic, 85% | 30% at 2 y | 47% at 2 y | 55% at 2 y |
| AITL, 3 | No difference by histology | No difference by histology | ||||||
| ALCL, 2 (2 ALK+) | ||||||||
| CTCL, 11 | ||||||||
| 58 | 24 | NOS, 9 | 53 | 25% | Acute, 25% (grade 2-4) Chronic, 30% | 25% | NR | 42% at 3 y |
| AITL, 5 | ||||||||
| ALCL, 4 |
| Reference . | n . | Histology; no. of patients* . | Median age, y . | NRM . | GVHD . | Relapse . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| 47 | 126 | NOS, 63 | 38 | MAC 34% | NR | MAC 37% | MAC 29% | MAC 31% |
| AITL, 12 | at 3 y | at 3 y | at 3 y | at 3 y | ||||
| ALCL, 51 | RIC 27% | RIC 42% | RIC 32% | RIC 50% | ||||
| at 3 y | at 3 y | at 3 y | at 3 y | |||||
| 52 | 77 | PTCL, 27 | 41 | 34% at 5 y | Acute 21% (grade 3-4) chronic NR | NR | 58% at 5 y | 63% at 5 y |
| AITL, 11 | 47 | 80% at 5 y | 80% at 5 y | |||||
| ALCL, 27 (8 ALK+) | 26 | 48% at 5 y | 55% at 5 y | |||||
| Other, 12 | 35 | NR | 33% at 5 y | |||||
| 93 | 66 | NOS, 23 | NR | 29% at day 100 | NR | NR | 46% at 1 y | 48% at 1 y |
| AITL, 12 | ||||||||
| ALCL, 11 | ||||||||
| T-LBL, 6 | ||||||||
| T-PLL, 7 | ||||||||
| Other, 7 | ||||||||
| 53 | 52 | NOS, 23 | 47 | 12% at 5 y | Acute, 22% (grade 2-4) chronic, 27% | 49% at 5 y | 39% at 5 y | 45% at 5 y |
| AITL, 9 | 44% at 5 y | 66% at 5 y | ||||||
| ALCL, 11 | 45% at 5 y | 54% at 5 y | ||||||
| No difference by histology | No difference by histology | |||||||
| 54 | 52 | NOS, 20 | 46 | 27% at 3 y | Acute, 21% | 43% at 3 y | 30% at 3 y | 41% at 3 y |
| AITL, 5 | (grade 2-4) | |||||||
| ALCL, 6 | Chronic, 27% | |||||||
| Other, 21 | (extensive) | |||||||
| 55 | 45 | AITL, 45 | 48 | 25% at 1 y | Acute, 29% (grade 2-4) Chronic, 54% | 20% at 3 y | 53% at 3 y | 64% at 3 y |
| 56 | 37 | NOS, 8 | 40 (50 for CTCL) | 29% at 5 y | Acute, 51% | 24% at 5 y | 47% at 5 y | 52% at 5 y |
| AILT, 4 | Chronic, 62% | |||||||
| ALCL, 6 (3 ALK+) | ||||||||
| Other, 6 | ||||||||
| CTCL, 13 | ||||||||
| 57 | 27 | NOS, 5 | 50 | 22% at 2 y | Acute, 33% (grade 2-3) Chronic, 85% | 30% at 2 y | 47% at 2 y | 55% at 2 y |
| AITL, 3 | No difference by histology | No difference by histology | ||||||
| ALCL, 2 (2 ALK+) | ||||||||
| CTCL, 11 | ||||||||
| 58 | 24 | NOS, 9 | 53 | 25% | Acute, 25% (grade 2-4) Chronic, 30% | 25% | NR | 42% at 3 y |
| AITL, 5 | ||||||||
| ALCL, 4 |
MAC, myeloablative conditioning; NR, not reported; T-LBL, T-cell lymphoblastic lymphoma; T-PLL, T-cell prolymphocytic leukemia.
Only major subtypes are listed: numbers do not add up to the total number of study patients,